Potential antipsychotic properties of central cannabinoid (CB₁) receptor antagonists

References

• Alonso R, Voutsinos B, Fournier M, et al. Blockade of cannabinoid receptors by SR 141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 1999; 91: 607–620
   PubMed Web of Science ®Google Scholar
• Auclair N, Otani S, Soubrie P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses. J Neurophysiol 2000; 83: 3287–3293
   PubMed Web of Science ®Google Scholar
• Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamate and GABAergic synaptic transmission in the lateral amygdale of the mouse. Learn Memory 2003; 10: 116–128
   PubMedGoogle Scholar
• Ballmaier M, Bortolato M, Rizzetti C, et al. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 2007; 32: 2098–2107
   PubMedGoogle Scholar
• Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999; 38: 34–43
   Google Scholar
• Bisogno T, Hanus L, De Petrocelis L, et al. Molecular targets for cannabidiol and its synthetic analogues:effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845–852
   PubMed Web of Science ®Google Scholar
• Bonnin A, de Miguel R, Castro JG, Raos JA. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J Mol Neurosci 1996; 7: 291–308
   PubMedGoogle Scholar
• Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol:possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998; 11: 1209–1216
   PubMed Web of Science ®Google Scholar
• Bortolato M, Aru GN, Fa M, Frau R, Orru M, Salis P, et al. Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle. Neuropsychopharmacology 2005; 30: 561–574
   PubMedGoogle Scholar
• Bosi DC, Hallak JEC, Dursun SM, Deakin JFW, Zuardi AW. Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J Psychopharmacol 2003; 17(Suppl)A55
   Google Scholar
• Braff D, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle:normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001; 156: 234–258
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155–163
   PubMed Web of Science ®Google Scholar
• Carlsson M, Carlsson A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?. Schizophr Bull 1990; 16: 425–432
   PubMed Web of Science ®Google Scholar
• Chen J, Paredes W, Lowinson JH, Gardner EL. Delta-9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmcol 1990; 190: 259–262
   PubMed Web of Science ®Google Scholar
• Chung, YC, Lee, CR, Park, TW, Yang, KH, Kim, KW. 2007. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial. World J Biol Psychiatry. July 10, 1–7, Epub ahead of print
   Google Scholar
• Collins DR, Pertwee RG, Davies SN. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 1995; 115: 869–870
   PubMed Web of Science ®Google Scholar
• Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175–185
   PubMed Web of Science ®Google Scholar
• Dall'Olio R, Rimondini R, Gandolfi O. The NMDA positive modulator d-cycloserine inhibits dopamine-mediated behaviors in the rat. Neuropharmacology 1994; 33: 55–59
   PubMedGoogle Scholar
• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9–15
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005; 353: 2121–2134
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–1949
   PubMed Web of Science ®Google Scholar
• Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998; 10: 2825–2830
   PubMed Web of Science ®Google Scholar
• Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol 1997; 7: 701–707
   PubMed Web of Science ®Google Scholar
• Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia:cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56: 803–807
   PubMed Web of Science ®Google Scholar
• Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005; 7: 268–274
   PubMedGoogle Scholar
• Ferrer B, Gorriti MA, Palomino A, et al. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. Eur J Pharmacol 2007; 559: 180–183
   PubMedGoogle Scholar
• Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39–44
   PubMed Web of Science ®Google Scholar
• Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117–154
   PubMed Web of Science ®Google Scholar
• Geyer MA, Markou A. Animal models of psychiatric disorders. Psychopharmacology: The fourth generation of progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 787–798
   Google Scholar
• Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci 1999; 2: 358–363
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108–2114
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998; 42: 707–711
   PubMedGoogle Scholar
• Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999; 46: 650–661
   PubMed Web of Science ®Google Scholar
• Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 1990; 87: 6912–6916
   PubMed Web of Science ®Google Scholar
• Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005; 4: 1083–1095
   PubMedGoogle Scholar
• Guimaraes VMC, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004; 75: 633–638
   PubMed Web of Science ®Google Scholar
• Hall W, Degenhardt L, Teesson M. Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 2004; 23: 433–443
   PubMed Web of Science ®Google Scholar
• Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1–4
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932–1936
   PubMed Web of Science ®Google Scholar
• Hernandez ML, Garcia-Gil L, Berrendro F, Ramos JA, Fernandez-Ruiz JJ. Delta-9-tetrahydrocannabinol increases the activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. J Mol Neurosci 1997; 8: 83–91
   PubMed Web of Science ®Google Scholar
• Hoffman HS, Ison JR. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 1980; 87: 175–189
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Andrusiak E, Tran A, Bowers MB, Jr, Roth RH. Delta–9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat:blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997; 16: 426–432
   PubMed Web of Science ®Google Scholar
• Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116–122
   PubMed Web of Science ®Google Scholar
• Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J. Acute effects of Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 2007; 97: 109–17
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine (D2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001a; 50: 873–883
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001b; 52: 503–517
   PubMed Web of Science ®Google Scholar
• Karper LP, Grillon C, Abi-Saab D, Morgan CA III. The effect of ketamine on pre-pulse inhibition and attention. Schizophr Res 1995; 15: 180
   Google Scholar
• Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158–164
   PubMed Web of Science ®Google Scholar
• Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997; 11: 123–131
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199–214
   PubMed Web of Science ®Google Scholar
• Krystal JH, D'Souza DC, Karper LP, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 1999; 145: 193–204
   PubMedGoogle Scholar
• Lapiz MD, Fulford A, Muchimapura S, Mason R, Parker T, Marsden CA. Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission. Neurosci Behav Physiol 2003; 33: 13–29
   PubMedGoogle Scholar
• Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665–1669
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000; 66: 175–181
   PubMed Web of Science ®Google Scholar
• Leweke FM, Gerth CW, Klosterkötter J. Cannabis-associated psychosis: current status of research. CNS Drugs 2004; 18: 895–910
   PubMed Web of Science ®Google Scholar
• Leweke, FM, Koethe, D, Gerth, CW, , et al. 2005. Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial on cannabidiol vs amisulpride in acute schizophrenia. 2005 Symposium on the CannabinoidsBurlington, Vermont
   Google Scholar
• Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995; 119: 282–290
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Martin BR. Δ9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996; 126: 125–131
   PubMedGoogle Scholar
• Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23: 223–239
   PubMed Web of Science ®Google Scholar
• Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006; 31: 795–803
   PubMedGoogle Scholar
• Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005; 20: 183–198
   PubMed Web of Science ®Google Scholar
• Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry 2003; 54: 121–128
   PubMed Web of Science ®Google Scholar
• Madsen MV, Peacock L, Werge T, Andersen MB. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. J Pharmacol 2006; 20: 622–628
   Google Scholar
• Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664–668
   PubMed Web of Science ®Google Scholar
• Mallet PE, Beninger RJ. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav Pharmacol 1996; 7: 276–284
   Web of Science ®Google Scholar
• Mallet PE, Beninger RJ. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta-9-tetrahydrocannabinol or anandamide. Psychopharmacology 1998; 140: 11–19
   PubMed Web of Science ®Google Scholar
• Malone DT, Taylor DA. The effect of Δ9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 2006; 166: 101–109
   PubMedGoogle Scholar
• Malone DT, Long LE, Taylor DA. The effect of SR141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol Biochem Behav 2004; 77: 839–845
   PubMedGoogle Scholar
• Mansbach RS, Rovetti CC, Winston EN, Lowe JA, III. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology 1996; 124: 315–322
   PubMed Web of Science ®Google Scholar
• Martin RS, Secchi RL, Sung E, et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology 2003; 165: 128–135
   PubMedGoogle Scholar
• Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994; 164: 679–681
   PubMed Web of Science ®Google Scholar
• Mato S, Pazos A, Valdizan EM. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A in cAMP production in human and rat brain. Eur J Pharmacol 2002; 443: 43–46
   PubMedGoogle Scholar
• McGuire PK, Jones P, Harvey I, et al. Cannabis and acute psychosis. Schizophr Res 1994; 13: 161–167
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Gaoni Y. A total synthesis of delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273–3275
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42: 11S–19S
   PubMed Web of Science ®Google Scholar
• Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17: 263–287
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233–255
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161: 975–984
   PubMed Web of Science ®Google Scholar
• Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 1999; 19: 6795–6805
   PubMed Web of Science ®Google Scholar
• Miyamoto A, Yamamoto T, Ohno M, et al. Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res 1996; 710: 234–240
   PubMedGoogle Scholar
• Monory K, Tzavara ET, Lexime J, et al. Novel, not adenylyl cyclase coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 2002; 292: 231–235
   PubMed Web of Science ®Google Scholar
• Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetics drugs in mice. Eur J Pharmacol 2005; 512: 199–205
   PubMed Web of Science ®Google Scholar
• Morgan JI, Curran T. Proto-oncogenes:beyond second messengers. Psychopharmacology: The fourth generation of progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 567–570
   Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–5
   PubMed Web of Science ®Google Scholar
• Nadulski T, Pragst F, Weinberg G, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 2005; 27: 799–810
   PubMed Web of Science ®Google Scholar
• Nakamura EM, da Silva EA, Concilio GV, Wilkinson DA, Masur J. Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 1991; 28: 167–175
   PubMedGoogle Scholar
• Olbrich, HM, Valerius, G, Rusch, N, , et al. 2007. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry. April 5, 1–5, Epub ahead of print
   Google Scholar
• Patel S, Hillard CJ. Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Res 2003; 963: 15–25
   PubMed Web of Science ®Google Scholar
• Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998; 63: PL1–6
   PubMed Web of Science ®Google Scholar
• Pistis M, Porcu G, Melis M, Diana M, Gessa GL. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 2001; 14: 96–102
   PubMed Web of Science ®Google Scholar
• Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 1999; 144: 144–150
   PubMed Web of Science ®Google Scholar
• Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006; 188: 425–444
   PubMed Web of Science ®Google Scholar
• Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 2005; 168: 445–477
   PubMedGoogle Scholar
• Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240–244
   PubMed Web of Science ®Google Scholar
• Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001; 21: 109–116
   PubMedGoogle Scholar
• Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain:contrasting effects of haloperidol and clozapine. Neuroscience 1992; 46: 315–328
   PubMed Web of Science ®Google Scholar
• Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5: 483–501
   PubMed Web of Science ®Google Scholar
• Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004; 174: 17–24
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, Parker BB. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037–1043
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092–1101
   PubMed Web of Science ®Google Scholar
• Scatton B, Sanger DJ. Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11: 243–256
   PubMedGoogle Scholar
• Schneider U, Borsutzky M, Seidert J, et al. Reduced binocular depth inversion in schizophrenic patients. Schizophr Res 2002; 53: 101–108
   PubMed Web of Science ®Google Scholar
• Schwartz RH. Marijuana: an overview. Pediatr Clin North Am 1987; 34: 305–317
   PubMed Web of Science ®Google Scholar
• Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16: 4322–4334
   PubMed Web of Science ®Google Scholar
• Shen M, Thayser SA. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1999; 55: 8–13
   PubMed Web of Science ®Google Scholar
• Solowij N. Cannabis and cognitive functioning. Cambridge University Press, Cambridge 1998
   Google Scholar
• Swerdlow NR, Kuczenski R, Goins JC, et al. Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol Biochem Behav 2005; 80: 203–211
   PubMedGoogle Scholar
• Terranova JP, Perio A, Worms P, Le Fur G, Soubrie P. Social olfactory recognition in rodents :deterioration with age, cerebral ischaemia and septal lesion. Behav Pharmacol 1994; 5: 90–98
   PubMedGoogle Scholar
• Terranova JP, Michaud JC, Le Fur G, Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 576–579
   PubMed Web of Science ®Google Scholar
• Terranova JP, Storme JJ, Lafon N, et al. Improvement of memory in rodents by selective CB1 cannabinoid receptor antagonist, SR141716. Psychopharmacology 1996; 126: 165–172
   PubMed Web of Science ®Google Scholar
• Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998; 285: 285–292
   PubMedGoogle Scholar
• Treffert DA. Marijuana use in schizophrenia: a clear hazard. Am J Psychiatry 1978; 135: 1213–1215
   PubMed Web of Science ®Google Scholar
• Turner WM, Tsuang MT. Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 1990; 16: 87–95
   PubMed Web of Science ®Google Scholar
• Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005; 76: 1–23
   PubMed Web of Science ®Google Scholar
• Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch Gen Psychiatry 2000; 57: 1139–1147
   PubMed Web of Science ®Google Scholar
• Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 2002; 51: 400–406
   PubMed Web of Science ®Google Scholar
• Varty GB, Higgins GA. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 1995; 122: 15–26
   PubMed Web of Science ®Google Scholar
• Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003; 49: 61–66
   PubMed Web of Science ®Google Scholar
• Vollenweider FX. Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998; 31: 92–103
   PubMedGoogle Scholar
• Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialog Clin Neurosci 2001; 3: 265–279
   PubMedGoogle Scholar
• Vollenweider FX, Geyer MA. A systems model of altered consciousness:integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56: 495–507
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers measured by FDG–PET. Eur Neuropsychopharmacol 1997; 7: 25–38
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry 2006; 60: 597–603
   PubMedGoogle Scholar
• Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 2007; 32: 1876–1887
   PubMedGoogle Scholar
• Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 1991; 104: 260–264
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56: 485–486
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20: 683–686
   PubMed Web of Science ®Google Scholar